Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies.
Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. · 2018
Read Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. by Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5920070.txt.
Introduction
Guo and co-authors review rheumatoid arthritis mechanisms and modern drug therapies. Their review appeared in Bone Research. Rheumatoid arthritis is a chronic autoimmune disease of joint linings. It brings progressive disability and early death for many. The review breaks disease into four stages. They run from triggering to a fulminant stage with bone erosion.
Each stage's pathology is set out in detail. Drug classes old and new are then reviewed. They include standard, biological, and small-molecule options. Many patients now reach remission without deformity. A large share still fail to respond well, the authors note. Next-generation drugs are thus badly needed.
Catalog record
| CREATOR | Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 91 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies By Qiang Guo, Yuxiang Wang, Dan Xu, Johannes Nossent, Nathan J. Pavlos, Jiake Xu Published in: Bone Research DOI: 10.1038/s41413-018-0016-9 ABSTRACT Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily affects the lining of the synovial joints and is associated with progressive disability, premature death, and socioeconomic burdens. A better understanding of how the pathological mechanisms drive the deterioration of RA progress in individuals is urgently required in order to develop therapies that will effectively treat patients at each stage of the disease progress. Here we dissect the etiology and pathology at specific stages: (i) triggering, (ii) maturation, (iii) targeting, and (iv) fulminant stage, concomitant with hyperplastic synovium, cartilage damage, bone erosion, and systemic consequences. Modern pharmacologic therapies (including conventional, biological, and novel potential small molecule disease-modifying anti-rheumatic drugs) remain the mainstay of RA treatment and there has been significant progress toward achieving disease remission without joint deformity. Despite this, a significant proportion of RA patients do not effectively respond to the current therapies and thus new drugs are urgently required. This review discusses recent advances of our understanding of RA pathogenesis, disease modifying drugs, and provides perspectives on next generation therapeutics for RA. INTRODUCTION Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that arises more frequently in females than males, being predominantly observed in the elderly. The prevalence rate reported in 2002 ranged from 0.5% to 1% of the population and had regional variation.1 RA primarily affects the lining of the synovial joints and can cause progressive disability, premature death, and socioeconomic burdens. The clinical manifestations of symmetrical joint involvement include arthralgia, swelling, redness, and even limiting the range of motion. Early diagnosis is considered as the key improvement index for the most desirable outcomes (i.e., reduced joint destruction, less radiologic progression, no functional disability, and disease modifying anti-rheumatic drugs (DMARD)-free remission) as well as cost-effectiveness as the first 12 weeks after early symptoms occur is regarded as the optimal therapeutic window.2–4 However, early diagnosis remains challenging as it relies heavily on the clinical information gathered from the patient’s history and physical examination supported by blood tests, and imaging analysis. The reasons for a delayed diagnosis vary markedly between countries with differing healthcare systems,5 while the reasons for a delay in initiating DMARD therapy in RA patients appear to be both patient- and physician-dependent. Noticeably, patient awareness of RA, the willingness of patients to seek medical advice, the time for the patients from symptom onset to receiving appropriate treatment, and the diagnostic capability of the physician all influence the treatment and outcome of RA. With poorly controlled or severe disease, there is risk that extra-articular manifestations such as keratitis, pulmonary granulomas (rheumatoid nodules), pericarditis/pleuritis, small vessel vasculitis, and other non-specific extra-articular symptoms will develop.Table 1Modern pharmacologic therapies for rheumatoid arthritis Classification Name Mechanism of action Potential mechanisms Side Effect Reference Conventional synthetic DMARDsMethotrexateAnalog of folic acidFolate-dependent processes; Adenosine signaling; Methyl-donor production; Reactive oxygen species; Adhesion-molecule expression; Cytokine profiles Eicosanoids and MMPs.Increased liver enzymes, pulmonary damage. 83 Leflunomide/ TeriflunomidePyrimidine synthesis inhibitorDHODH-dependent pathway; Leukocyte adhesion; Rapidly dividing cells; NF-kB; Kinases; Interleukins; TGF-β.Hypertension, diarrhea and nausea, hepatotoxicity. 153 SulfasalazineAnti-inflammatory and immunosuppressionCyclooxygenase and PGE2; Leukotriene production and chemotaxis; Inflammatory cytokines (IL-1, IL-6, TNF-α); Adenosine signaling; NF-kB activation.Gastrointestinal, central nervous system, and hematologic adverse effect. 154 Chloroquine /HydroxychloroquineImmunomodulatory effectsToll-like receptors; Lysosomotropic action; Monocyte-derived pro-inflammatory cytokines; Anti-inflammatory effects; Cellular immune reactions; T cell responses; Neutrophils; Cartilage metabolism and degradation.Gastrointestinal tract, skin, central nervous system adverse effect and retinal toxicity. 155 Biological DMARDsAntibody-based therapiesTNF-α targeted therapyInfliximabTNF-α inhibitorPhagocytosis and pro-inflammatory cytokines; Chemoattractant; Adhesion molecules and chemokines; Treg cell function; Function of osteoclasts, leukocytes, endothelial and synovial fibroblasts.Infection (pneumonia and atypical tuberculosis) injection-site reaction.AdalimumabHypertension.EtanerceptSevere /anaphylactoid transfusion reaction. 156 GolimumabCertolizumab pegolB-cell targeted therapyRituximabB cell depletingFc receptor gamma-mediated antibody-dependent cytotoxicity and phagocytosis; Complement-mediated cell lysis; antigen presentation; B cell apoptosis; Depletion of CD4+ T cells.Infection, hypertension, hypogammaglobulinemia, viral reactivation, vaccination responses.OfatumumabLate-onset neutropenia.BelimumabInhibitors of B cell functionSevere/anaphylactoid transfusion reaction. 157 AtaciceptTabalumabT-cell targeted therapyAbataceptCD28/CTLA4 systemAutoantigen recognition; Immune cell infiltrate; T cells activation.Infection, malignancy. 158 BelataceptCD80/CD86Interleukin targeted therapyTocilizumabIL-6 inhibitionInnate and the adaptive immune system perturbation; Acute-phase proteins.Infections (most notably skin and soft tissue), increases in serum cholesterol, transient decreases in neutrophil count and abnormal liver function. 159 AnakinraIL-1 inhibitionInflammatory responses; Matrixenzyme.Injection site reactions, infections, neutropenia, malignancy.Canakinumab 160 RilonaceptSecukinumabIL-17 inhibitionMitochondrial function; Autophagosome formation.Infections, nasopharyngitis, candidiasis, neutropenia, safety data of mental health is limited. 161 IxekizumabGrowth and differentiation factorsDenosumabRANKL inhibitorMaturation and activation of osteoclast.Low Ca2+ and phosphate in the blood, muscle cramps, cellulitis, and numbness. 162 MavrilimumabGM-CSF inhibitorActivation, differentiation, and survival of macrophages, dendritic cells, and neutrophils; T helper 1/17 cell; modulation of pain pathways.Safety file needs further research. 143 Small moleculesJAK pathwayTofacitinibJAK1 and JAK3 inhibitorT-cell activation, pro-inflammatory cytokine production, synovial inflammation, and structural joint damage.Zoster infection (advice is to vaccinate beforehand) and other potential side-effects should be monitored carefully through further study.BaricitinibJAK1 and JAK2 inhibitor 163, 164 FilgotinibJAK1 inhibitorFuture drug and targetToll like receptors;165 Bruton’s tyrosine kinase;151 Phosphoinositide-3-kinase pathway;166 Transforming growth factor-beta;167 Neuropathways;168 Dendritic cell169 While there is currently no cure for RA, the treatment strategy aims to expedite diagnosis and rapidly achieve a low disease activity state (LDAS). There are many composite scales measuring the disease activity such as the Disease Activity Score using 28 joints (DAS-28), Simplified Disease Activity Assessment Index (SDAI), and Clinical Disease Assessment Index (CDAI).6 To achieve full suppression of the activity of the disease (clinical remission), rheumatologists need to monitor disease activity continuously and accurately and to adjust the treatment regimen accordingly. Universally applied pharmacologic therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids have proven effective in relieving stiffness and pain, but do not moderate disease progression. Over the last 20 years, the effectiveness of DMARDs has gained much attention as these can efficiently attenuate disease activity and substantially decrease and/or delay joint deformity.7 The therapy classification includes the traditional synthetic drugs, biological DMARDs, and novel potential small molecules. Historical DMARDs such as auranofin, minocycline, azathioprine, and cyclosporine are rarely implemented as modern therapies. Several biological DMARDs have recently emerged including TNF-inhibitor (Amjevita, Renflexis, Erelzi, Cyltezo, Imradl), anti-CD20 antibody (Truxima, Rixathon), IL-6 receptor antibody (Kevzara), RANKL antibody (Pralia), and JAK inhibitor (Olumiant). Despite the increasing number of new drugs and treatment regimes, complete long-term disease remission is not achieved for many patients and thus new therapeutic options are required. This review provides a contemporary appraisal of recent literature on the pathogenesis of RA and the potential of new pharmacological interventions for optimizing RA treatment regimes. PATHOGENESIS OF RA There are two major subtypes of RA according to the presence or absence of anti-citrullinated protein antibodies (ACPAs). Citrullination is catalyzed by the calcium-dependent enzyme peptidyl-arginine-deiminase (PAD), changing a positively charged arginine to a polar but neutral citrulline as the result of a post-translational modification. ACPAs can be detected in approximately 67% of RA patients and serve as a useful diagnostic reference for patients with early, undifferentiated arthritis and provide an indication of likely disease progression through to RA.8,9 The ACPA-positive subset of RA has a more aggressive clinical phenotype compared to ACPA-negative subset of RA.10 It is reported that ACPA-negative RA has different genetic association patterns11 and differential responses of immune cells to citrullinated antigens12 from those of